Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Copart Set to Join S&P 500; Exelixis to Join S&P MidCap 400; Clarifications to S&P U.S. Indices Methodology

PR Newswire June 25, 2018

Consolidated Research: 2018 Summary Expectations for Rayonier Advanced Materials, CYS Investments, Avid Bioservices, American Airlines Group, Exelixis, and International Business Machines — Fundamental Analysis, Key Performance Indications

GlobeNewswire June 14, 2018

Exelixis to Present at the William Blair & Co. 38th Annual Growth Stock Conference on June 12, 2018

Business Wire June 5, 2018

The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Benzinga.com  June 3, 2018

Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018

Business Wire June 3, 2018

Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

Business Wire June 1, 2018

Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Benzinga.com  May 30, 2018

Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma

Business Wire May 29, 2018

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Benzinga.com  May 26, 2018

Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy

Business Wire May 22, 2018

Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

Business Wire May 17, 2018

40 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  May 10, 2018

Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Benzinga.com  May 10, 2018

32 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  May 10, 2018

Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer

Business Wire May 10, 2018

Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018

Business Wire May 8, 2018

Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Benzinga.com  May 3, 2018

Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer

Business Wire May 2, 2018

Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update

Business Wire May 2, 2018

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Benzinga.com  May 2, 2018